^
    Back
    Association details:
    Biomarker:TSC2 mutation
    Cancer:Renal Cell Carcinoma
    Drug Class:mTOR inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Comprehensive molecular and immunohistochemical analysis of advanced renal cell carcinoma patients treated with mTOR inhibitors.

    Published date:
    05/16/2018
    Excerpt:
    TSC1, TSC2 and MTOR mutations only partially correlated with response. Lack of BAP1 and PBRM1 expression was associated with improved response to mTOR inhibitors.
    DOI:
    10.1200/JCO.2018.36.15_suppl.4559